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Abstract
Background. Thecalcimimetic,cinacalcet, isapproved for
treatingsecondaryhyperparathyroidism(SHPT)inpatients
with chronic kidney disease (CKD) on dialysis. Biochemi-
cal profiles and clinical outcomes in patients discontinuing
cinacalcet at kidney transplantation have not been previ-
ously described.
Methods. We performed a retrospective observational
study evaluating post-transplant biochemical profiles and
clinical outcomes in patients who had enrolled in phase 2
or 3 randomized, placebo-controlled studies of cinacalcet
before receiving a kidney transplant.
Results. The study included 28 former cinacalcet and 10
former placebo patients. Post-kidney transplant, there were
no obvious differences between the two groups in levels
of serum intact parathyroid hormone, calcium or phospho-
rus. One patient in each group underwent post-transplant
parathyroidectomy. Kidney transplant failure was appar-
ent in one former cinacalcet-treated patient (4%) and three
formerplacebopatients(30%).Thedurationofhospitaliza-
tion (mean ± standard error) immediately post-transplant
in these two groups was 2.3 ± 0.3 and 3.4 ± 0.8 weeks,
respectively.
Conclusions. Using cinacalcet to treat SHPT in patients
with CKD awaiting kidney transplantation does not appear
to modify SHPT-related post-transplant biochemical pro-
files, or clinical outcomes, compared with placebo.
Keywords: cinacalcet; end-stage renal disease; kidney transplantation;
secondary hyperparathyroidism
Introduction
Secondary hyperparathyroidism (SHPT) is a common
complication of chronic kidney disease (CKD). The cal-
cimimetic, cinacalcet, is approved for treating SHPT in
CKD patients receiving dialysis. Randomized, double-
blind, placebo-controlled clinical trials in dialyzed pa-
tients with SHPT have shown cinacalcet to lower serum
parathyroid hormone (PTH), phosphorus, calcium and the
calcium–phosphorus product (Ca × P) [1–4]. Cinacalcet
facilitates achievement of the National Kidney Founda-
tion’s Kidney Disease Outcomes Quality Initiative (NKF-
K/DOQITM) recommended targets for serum PTH, phos-
phorus, calcium and Ca × P [4,5].
Patients undergoing kidney transplantation may have re-
ceived cinacalcet before the procedure. However, the bio-
chemical profile of patients who discontinue cinacalcet at
the time of their transplant has not been previously de-
scribed.Wereportaretrospective,observationalstudyeval-
uatingpost-transplantbiochemicalprofilesandclinicalout-
comes in such patients.
Subjects and methods
Patients
Patients were included in this study if they had withdrawn
fromaqualifyingphase2or3Amgen-sponsoredcinacalcet
study to receive a kidney transplant. All patients signed an
informed consent form.
Study design
This was an observational, retrospective study. No inter-
ventional procedures were undertaken. Patients did not re-
ceive cinacalcet after kidney transplantation; if they had
been treated with cinacalcet during the qualifying study,
the drug was withdrawn when patients left the qualifying
study.
Data collection
Local laboratory data relating to serum PTH, calcium and
phosphorus levels were collected when patients left the
qualifying study, before kidney transplantation and up to
12 months afterwards. Only serum intact (i)PTH mea-
surements were included in this analysis. Information re-
lated to the incidences of parathyroidectomy and kidney
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Table 1. Demographic characteristics of the patients followed up in this study (recorded when patients entered the qualifying study from which they
subsequently withdrew)
Former placebo patients (n = 10) Former cinacalcet patients (n = 28)
Age (years)
Mean ± SE 43.7 ± 3.7 53.3 ± 2.0
Sex, n (%)
Male 10 (100) 20 (71)
Race, n (%)
White or Caucasian 8 (80) 18 (64)
Black or African American 1 (10) 9 (32)
Other 1 (10) 1 (4)
Duration of exposure to treatmenta (days)
Mean ± SE 213 ± 82 290 ± 30
Duration of dialysis (months)
Mean ± SE 52 ± 14 57 ± 12
Time from last dose in previous study to kidney transplantation (days)
Mean ± SE 1.4 ± 0.6 3.6 ± 2.3
SE = standard error.
aDuration of exposure does not include gaps between studies for patients participating in more than one qualifying study.
transplant failure, duration of post-transplant hospital-
ization and post-transplant creatinine clearance was also
recorded.
Statistical methods
The sample size was determined by the number of patients
participating in a qualifying study, withdrawing before kid-
ney transplantation and consenting to follow-up. Data were
analysed using descriptive statistics. Between-group com-
parisons were performed using the chi-square test (categor-
ical variables) and Student’s t-test or the Mann–Whitney
test (continuous variables). P < 0.05 was considered statis-
tically significant.
Results
Patients
Of 107 eligible patients (68 cinacalcet and 39 placebo), 38
(36%) (28former cinacalcet, 10 former placebo) consented
tofollow-up,thedemographiccharacteristicsofwhomwere
broadly representative of the overall eligible patient popu-
lation(datanotshown).Thedemographic andbaseline bio-
chemical characteristics of the study population are shown
in Tables 1 and 2. The mean values for iPTH, phospho-
rus and calcium levels on entry to the qualifying study
among patients consenting to the follow-up were similar
to those of the overall eligible patient population (data not
shown).
Evaluation of post-transplant biochemical parameters and
clinical outcomes
Consistently measured iPTH data were available for only
7/28 former cinacalcet patients; The mean ± standard error
(SE) serum iPTH values at the qualifying-study baseline,
kidney transplant and 1, 6 and 12 months after transplanta-
tion were 881 ± 160 (n = 7), 568 ± 325 (n = 7), 557 ±
243 (n = 7), 481 ± 205 (n = 7) and 880 ± 588 (n = 5)
pg/ml, respectively (93 ± 17, 60 ± 34, 59 ± 26, 51 ± 22
93 ± 62 pmol/l, respectively). The corresponding median
(Q1, Q3) values were 970 (399, 1249), 226 (136, 712), 229
(173, 1175), 322 (156, 528) and 393 (191, 471) pg/ml, re-
spectively. No regular iPTH measurements were available
forformerplacebopatients.Twelvemonthspost-transplant,
based on all patients who had available data at this time
point, the mean ± SE iPTH values for the former cinacal-
cet (n = 7) and former placebo (n = 5) groups were 769 ±
415 pg/ml (82 ± 44 pmol/l) and 674 ± 301 pg/ml (72 ±
32 pmol/l), respectively. The mean value in former cinacal-
cet patients was heavily influenced by one patient with a
veryhighiPTHconcentration(3219pg/ml);thispatienthad
very high iPTH levels throughout the study (712 pg/ml,
1750 pg/ml, 1663 pg/ml at the qualifying-study baseline
and 1 and 6 months after transplantation). The trans-
plant failed in this patient; creatinine clearance was only
recorded at Week 1. Excluding this patient, the mean ±
SE iPTH value was 361 ± 86 pg/ml (38 ± 9.2 pmol/l)
at Month 12. The median (Q1, Q3) values at Month 12
for the former cinacalcet and placebo patients were
393 (191, 706) and 245 (159, 1302) pg/ml, respectively
(Table 2). Median iPTH values at other time points,
for both former cinacalcet and former placebo patients
for whom data were available, are presented in Table 2.
Despite the small number of patients evaluated and the
variability of the data, there did not appear to be any ob-
vious difference between the two patient groups. One for-
mer cinacalcet patient (4%) and one former placebo patient
(10%) underwent post-transplant parathyroidectomy.
In both groups, mean total calcium levels remained sim-
ilar and relatively unchanged (Table 2) and mean plasma
phosphorusconcentrationsdecreasedduringthefirstmonth
post-transplant, but remained relatively unchanged there-
after (Table 2).
Kidney transplant failure was apparent in one former
cinacalcet-treated patient (4%) and three former placebo
patients (30%); the mean ± SE duration of hospitaliza-
tion immediately post-transplant in these two groups wasE
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Table 2. Biochemical parameters before and after kidney transplantation in patients who had received either cinacalcet or placebo prior to the transplant and consented to follow-upa
At the end of the qualifying
On entry to the qualifying study and before kidney
study transplant 1 month post-transplant 6 months post-transplant 12 months post-transplant
Former Former Former Former Former Former Former Former Former Former
placebo cinacalcet placebo cinacalcet placebo cinacalcet placebo cinacalcet placebo cinacalcet
patients patients patients patients patients patients patients patients patients patients
iPTH (pg/ml)b 552 607 542 225 221 229 741 322 245 393
[413, 960]e [484, 925]e [424, 785]e [131, 611]e [221, 221]e [173, 1175]e [68, 851]e [156, 491]e [159, 1302]e [191, 706]e
676 ± 114 701 ± 57 876 ± 241 415 ± 105 221 557 ± 243 553 ± 245 409 ± 134 674 ± 301 769 ± 415
(n = 10) (n = 28) (n = 9) (n = 24) (n = 1) (n = 7) (n = 3) (n = 11) (n = 5) (n = 7)
Calcium (mg/dl)c 9.6 ± 0.2 9.8 ± 0.1 9.6 ± 0.3 9.5 ± 0.2 9.9 ± 0.3 10.1 ± 0.2 10.1 ± 0.3 10.3 ± 0.2 10.4 ± 0.3 10.9 ± 0.5
(n = 10) (n = 28) (n = 8) (n = 23) (n = 9) (n = 27) (n = 9) (n = 27) (n = 9) (n = 19)
Phosphorus (mg/dl)d 6.2 ± 0.6 6.4 ± 0.3 6.9 ± 0.8 5.2 ± 0.3 2.4 ± 0.3 2.2 ± 0.1 2.9 ± 0.2 2.7 ± 0.1 3.8 ± 0.7 3.0 ± 0.2
(n = 10) (n = 28) (n = 10) (n = 27) (n = 10) (n = 28) (n = 8) (n = 27) (n = 8) (n = 18)
iPTH = intact parathyroid hormone.
aData are missing for some patients.
biPTH: 1 pmol/l = 1 pg/ml × 0.10611.
cCalcium: 1 mmol/l = 1 mg/dl × 0.25.
dPhosphorus: 1 mmol/l = 1 mg/dl × 0.323
eMedian [Q1, Q3] values
For iPTH, median [Q1, Q3], mean ± standard error values, and the number of patients on whom data are based, are shown. For calcium and phosphorus, mean ± standard error values are shown, together with
the number of patients on whom the data are based.40 M. Jadoul et al.
Fig. 1. Mean rates of creatinine clearance following kidney transplantation in patients who had received either cinacalcet or placebo prior to the
transplant. Estimated glomerular filtration rate was calculated based on the Cockcroft and Gault formula [6]. Error bars represent standard errors.
2.3 ± 0.3 and 3.4 ± 0.8 weeks, respectively; mean val-
ues for creatinine clearance appeared consistently higher in
former cinacalcet patients than former placebo (Figure 1).
These differences were not statistically significant.
Discussion
The results from this study suggest that using cinacalcet
to treat SHPT in patients with CKD awaiting kidney trans-
plantation does not appear to modify SHPT-related post-
transplant biochemical profiles compared with placebo.
Limited data also suggest that cinacalcet does not appear
to modify post-transplant clinical outcomes. In addition,
former cinacalcet-treated patients did not appear to show
large post-transplant changes in iPTH in our study—it is
important that cinacalcet does not adversely impact on the
post-transplant outcome of resistant hyperparathyroidism.
However, our findings should be interpreted with caution
because of the small sample size, within-group variability
of the biochemical parameters we described and the pos-
sibility of bias. Its retrospective design made this study
susceptible to population bias, but patients recruited were
broadly representative of the overall eligible patient pop-
ulation from which they had been drawn. There was no
patient selection bias within participating centres—all eli-
gible patients were invited to enrol. However, measurement
bias was a possibility—patients for whom no iPTH mea-
surements were obtained may have had less severe SHPT,
in which case an effect of cinacalcet may have been missed.
Finally, the iPTH assays were measured at local laborato-
riesandconsequentlytheremayhavebeensomedifferences
between assays that were not taken into account.
Although kidney transplantation can correct some
abnormalities that result in SHPT and studies of early
post-transplant changes [7,8] show that PTH levels may
decrease, PTH may not completely normalize and data ob-
tained 12 months post-transplant show that hyperparathy-
roidism may not have resolved [7]. Indeed, observational
research examining post-transplant parameters has shown
persistenthyperparathyroidismin∼17%ofpatients[9].Pa-
tients with moderate-to-severe SHPT before kidney trans-
plant had a higher rate of persistent hyperparathyroidism
(∼30%) and an incidence of hypercalcaemia of ∼50% dur-
ingthefirstyearpost-transplant[9].Inseveralsmallstudies
of up to 6-month duration, cinacalcet controlled persistent
hyperparathyroidisminkidneytransplantrecipients,signif-
icantly reducing serum calcium and PTH levels [10–18].
These studies indicate that cinacalcet is a promising thera-
peutic option for kidney transplant patients with persistent
hyperparathyroidism,andapotentialalternativetoparathy-
roidectomy. Additional research is warranted to determine
whether cinacalcet treatment should be withdrawn or con-
tinued in the peri- and post-transplant periods in patients
with severe SHPT during dialysis.
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